WORCESTER, Mass., June 3, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) presented final results of the Phase I trial of the Company's novel AE37 immunotherapeutic vaccine in breast cancer patients at the 44th annual meeting of the American Society of Clinical Oncology (ASCO, www.asco.org) in Chicago, Illinois held May 30 through June 3. AE37, a therapeutic vaccine, is being developed by the Company's wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), for a number of indications in oncology. The Phase I trial concluded the vaccine was safe and well tolerated in breast cancer patients.
